KR20220165797A - 내장통 치료용 옥시코돈의 사용 - Google Patents

내장통 치료용 옥시코돈의 사용 Download PDF

Info

Publication number
KR20220165797A
KR20220165797A KR1020227041445A KR20227041445A KR20220165797A KR 20220165797 A KR20220165797 A KR 20220165797A KR 1020227041445 A KR1020227041445 A KR 1020227041445A KR 20227041445 A KR20227041445 A KR 20227041445A KR 20220165797 A KR20220165797 A KR 20220165797A
Authority
KR
South Korea
Prior art keywords
oxycodone
pain
visceral pain
present
morphine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227041445A
Other languages
English (en)
Korean (ko)
Inventor
아스브요른 모어 드류즈
라르 아렌트 닐센
Original Assignee
유로-셀티큐 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35871217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20220165797(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 유로-셀티큐 에스.에이. filed Critical 유로-셀티큐 에스.에이.
Priority to KR1020237042001A priority Critical patent/KR20230170811A/ko
Publication of KR20220165797A publication Critical patent/KR20220165797A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020227041445A 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용 Ceased KR20220165797A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237042001A KR20230170811A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64549005P 2005-01-18 2005-01-18
US60/645,490 2005-01-18
PCT/EP2006/050252 WO2006077212A1 (en) 2005-01-18 2006-01-17 Use of oxycodone for treating visceral pain
KR1020217034339A KR20210131450A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217034339A Division KR20210131450A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237042001A Division KR20230170811A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용

Publications (1)

Publication Number Publication Date
KR20220165797A true KR20220165797A (ko) 2022-12-15

Family

ID=35871217

Family Applications (10)

Application Number Title Priority Date Filing Date
KR1020207031796A Ceased KR20200128451A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020077018905A Ceased KR20070100368A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020227041445A Ceased KR20220165797A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020147018838A Ceased KR20140091782A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020237042001A Ceased KR20230170811A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020177004572A Ceased KR20170021905A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020127011713A Ceased KR20120089710A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020217034339A Ceased KR20210131450A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020087029312A Ceased KR20080106991A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020197035201A Ceased KR20190135557A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020207031796A Ceased KR20200128451A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020077018905A Ceased KR20070100368A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용

Family Applications After (7)

Application Number Title Priority Date Filing Date
KR1020147018838A Ceased KR20140091782A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020237042001A Ceased KR20230170811A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020177004572A Ceased KR20170021905A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020127011713A Ceased KR20120089710A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020217034339A Ceased KR20210131450A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020087029312A Ceased KR20080106991A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020197035201A Ceased KR20190135557A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용

Country Status (31)

Country Link
US (2) US20080200493A1 (enExample)
EP (1) EP1838318B1 (enExample)
JP (1) JP5049139B2 (enExample)
KR (10) KR20200128451A (enExample)
CN (1) CN101106996B (enExample)
AP (1) AP2249A (enExample)
AR (1) AR052880A1 (enExample)
AT (2) ATE446092T1 (enExample)
AU (1) AU2006207498B2 (enExample)
BR (1) BRPI0606247A2 (enExample)
CA (1) CA2595043C (enExample)
CY (1) CY1109660T1 (enExample)
DE (2) DE602006009899D1 (enExample)
DK (2) DK1838318T3 (enExample)
EA (1) EA013544B1 (enExample)
ES (1) ES2333901T3 (enExample)
HR (1) HRP20090679T1 (enExample)
IL (1) IL184530A (enExample)
ME (1) ME01066B (enExample)
MX (1) MX2007007207A (enExample)
MY (1) MY144471A (enExample)
NO (1) NO338968B1 (enExample)
NZ (1) NZ555852A (enExample)
PL (1) PL1838318T3 (enExample)
PT (1) PT1838318E (enExample)
RS (1) RS51069B (enExample)
SI (1) SI1838318T1 (enExample)
TW (1) TWI432196B (enExample)
UA (1) UA85471C2 (enExample)
WO (1) WO2006077212A1 (enExample)
ZA (1) ZA200705231B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3045182T3 (en) 2005-11-14 2018-03-19 Teva Pharmaceuticals Int Gmbh ANTAGONIST ANTIBODIES AGAINST CALCITONIN GEN-RELATED PEPTIDE TO TREAT HEAT
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
WO2009109911A1 (en) 2008-03-04 2009-09-11 Pfizer Limited Methods of treating chronic pain
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
RU2535074C2 (ru) * 2009-08-28 2014-12-10 Лэйбрис Байолоджикс, Инк. Способы лечения висцеральной боли путем введения антител-антагонистов, направленных против пептида, связанного с геном кальцитонина
TWI692485B (zh) 2011-05-20 2020-05-01 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途
CN103702685B (zh) 2011-05-20 2017-12-15 奥尔德生物控股有限责任公司 抗cgrp抗体和抗体片段用于在有需要的受试者、尤其是偏头痛患者中预防或抑制畏光或厌光的用途
KR102128628B1 (ko) 2011-05-20 2020-06-30 앨더바이오 홀딩스 엘엘씨 설사의 만성 및 급성 형태를 치료 또는 예방하기 위한 항-cgrp 또는 항-cgrp-r 항체 또는 항체 단편의 용도
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
RS65360B1 (sr) 2014-03-21 2024-04-30 Teva Pharmaceuticals Int Gmbh Antagonistička antitela specifična za peptid genski srodan kalcitoninu i postupci njihove upotrebe
AU2017331593B2 (en) 2016-09-23 2022-04-28 Teva Pharmaceuticals International Gmbh Treating refractory migraine
JP7472116B2 (ja) 2018-11-19 2024-04-22 ジャズ ファーマシューティカルズ アイルランド リミテッド 耐アルコール性製剤
US11639380B2 (en) 2019-01-08 2023-05-02 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-CGRP antibodies
SG10202003296VA (en) 2020-04-06 2021-11-29 H Lundbeck As Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
CN1494907A (zh) * 1996-03-25 2004-05-12 治疗疼痛的药物组合物
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US6992193B2 (en) * 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use

Also Published As

Publication number Publication date
RS51069B (sr) 2010-10-31
KR20200128451A (ko) 2020-11-12
DK200700207U3 (da) 2007-09-28
CN101106996B (zh) 2013-10-23
KR20120089710A (ko) 2012-08-13
HK1107933A1 (en) 2008-04-25
UA85471C2 (ru) 2009-01-26
CA2595043C (en) 2013-11-19
MY144471A (en) 2011-09-30
DK200700207U1 (da) 2007-08-24
DK1838318T3 (da) 2010-01-04
US20080200493A1 (en) 2008-08-21
KR20230170811A (ko) 2023-12-19
NO338968B1 (no) 2016-11-07
ATE446092T1 (de) 2009-11-15
US9271974B2 (en) 2016-03-01
NO20074174L (no) 2007-10-17
ES2333901T3 (es) 2010-03-02
KR20070100368A (ko) 2007-10-10
PT1838318E (pt) 2009-12-15
EP1838318B1 (en) 2009-10-21
US20150190393A1 (en) 2015-07-09
DE602006009899D1 (de) 2009-12-03
SI1838318T1 (sl) 2010-02-26
ME01066B (me) 2012-10-20
IL184530A0 (en) 2007-10-31
KR20170021905A (ko) 2017-02-28
MX2007007207A (es) 2007-08-15
NZ555852A (en) 2010-01-29
TWI432196B (zh) 2014-04-01
EA200701541A1 (ru) 2008-02-28
HRP20090679T1 (hr) 2010-01-31
AP2007004057A0 (en) 2007-08-31
AT9895U1 (de) 2008-05-15
KR20190135557A (ko) 2019-12-06
CA2595043A1 (en) 2006-07-27
EP1838318A1 (en) 2007-10-03
CY1109660T1 (el) 2014-08-13
KR20080106991A (ko) 2008-12-09
WO2006077212A1 (en) 2006-07-27
AU2006207498A1 (en) 2006-07-27
AP2249A (en) 2011-07-18
DE202006019887U1 (de) 2007-07-26
IL184530A (en) 2015-01-29
AR052880A1 (es) 2007-04-11
CN101106996A (zh) 2008-01-16
JP2008526927A (ja) 2008-07-24
BRPI0606247A2 (pt) 2009-06-09
AU2006207498B2 (en) 2009-11-19
JP5049139B2 (ja) 2012-10-17
PL1838318T3 (pl) 2010-03-31
ZA200705231B (en) 2008-06-25
KR20140091782A (ko) 2014-07-22
TW200637554A (en) 2006-11-01
KR20210131450A (ko) 2021-11-02
EA013544B1 (ru) 2010-06-30

Similar Documents

Publication Publication Date Title
US9271974B2 (en) Use of oxycodone for treating visceral pain
CZ292849B6 (cs) Farmaceutický prostředek s řízeným uvolněním oxykodonu
KR20070107805A (ko) 옥시코돈 및 날록손 함유 제형
JP2016074728A (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
HK1107933B (en) Use of oxycodone for treating visceral pain
WO2005016319A2 (en) Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
AU2019216647A1 (en) Reducing drug liking in a subject

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A17-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

J201 Request for trial against refusal decision
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

J121 Written withdrawal of request for trial
PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202

PJ1201 Withdrawal of trial

St.27 status event code: A-3-3-V10-V13-apl-PJ1201